Could a supplement boost prostate cancer treatment?

NCT ID NCT07389174

Not yet recruiting Disease control Sponsor: Shanghai Changzheng Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests whether adding a dietary supplement called LC-K76 to standard hormone therapy is safe for men with metastatic hormone-sensitive prostate cancer. Forty men will receive the supplement plus hormone therapy for 24 weeks, then be followed for another 24 weeks. The main goal is to check for side effects, but researchers will also look at PSA levels and how long it takes for the cancer to become resistant to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LC-K76 (a dietary supplement)
What this could lead to: If it works, this could point toward a way to improve standard hormone therapy for metastatic prostate cancer.
What could go wrong: This is a very early, small trial (40 people) focused on safety, not proof of effectiveness. The supplement may not provide any added benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MHNPC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MHNPC MHSPC PROSTATE CANCER (ADENOCARCINOMA)

Contacts and locations

Locations

Changzheng hospital

Shanghai, Shanghai Municipality, 201109, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.